Concentra Biosciences’ spread-betting on biotech acquisitions has finally reeled in another win in 2023, with Theseus Pharmaceuticals taking up the offer of the buyout.
Over the last few weeks, Theseus had been mulling offers from both Tang Capital-owned Concentra and the VC firms Foresite and Orbimed. Now, it has announced that it’s opting for the former.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,